By Christian Moess Laursen
Argent BioPharma said it plans to leave the London Stock Exchange while mulling a listing in the U.S.
The pharmaceutical company, which will keep its stock-market listing in Australia, said it has taken steps to cancel the admission of its shares on the LSE.
The decision followed a review of both the listing requirements and costs associated with the transfer of all its ordinary shares, it said Friday.
Argent Biopharma expects the last day of trading on the LSE to be Dec. 31.
The company said it might still look to explore opportunities to expand its accessibility to investors, including a potential listing on an U.S. exchange.
The company's main operations and management are based in the EU, with a growing investor base in the U.S.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
November 29, 2024 02:57 ET (07:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.